Company Encyclopedia
View More
name
Candel Therapeutics
CADL.US
Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase III clinical trials for the treatment of prostate cancer; Phase II clinical trials for the treatment of pancreatic cancer; and Phase II clinical trials for the treatment of non-small cell lung cancer (NSCLC). The company is also developing CAN-3110, which is in Phase Ib clinical trials for the treatment of recurrent high-grade glioma. In addition, it develops the?enLIGHTEN Discovery Platform, a systematic, iterative herpes simplex virus based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapy candidates for solid tumors.
1.912 T
CADL.USMarket value -Rank by Market Cap -/-

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Canaccord Genuity Sticks to Their Buy Rating for Candel Therapeutics (CADL)

    Canaccord Genuity analyst John Newman maintained a Buy rating for Candel Therapeutics (CADL) with a price target of $25.00. Newman, a 2-star analyst, has an average return of 0.1% and a 39.16% success rate. Candel Therapeutics also received a Buy rating from H.C. Wainwright, while Bank of America Securities maintained a Hold rating.

    Tip Ranks·
    US
    CADL
    +0.54%
    Tip Ranks·
    US
    CADL
    +0.54%

    Candel Therapeutics Showcases Advances in Immune-Based Cancer Therapies in New Corporate Presentation

    Candel Therapeutics Inc. has released a corporate presentation showcasing advances in immune-based cancer therapies, highlighting positive results for CAN-2409 in various cancer trials. The company reports a strong financial position with $87 million in cash and a $130 million term loan facility. Precommercialization activities for CAN-2409 are underway, with key milestones anticipated for 2025-2026, including updated clinical results and new phase 3 trials.

    Reuters·
    US
    CADL
    +0.54%
    Reuters·
    US
    CADL
    +0.54%

    Brookline Capital Management Weighs in on CADL Q4 Earnings

    Brookline Capital Management estimates Candel Therapeutics will earn ($0.22) per share in Q4 2025. The stock has a consensus rating of "Moderate Buy" with a price target of $18.33. Recent ratings include "outperform" and "buy," but Bank of America downgraded it to "neutral." Institutional investors have adjusted their stakes, with hedge funds owning 13.93% of the stock. Candel Therapeutics develops immunotherapies for cancer, with several ongoing clinical trials.

    Market Beat·
    US
    CADL
    +0.54%
    Market Beat·
    US
    CADL
    +0.54%

    Candel Therapeutics’ Promising CAN-2409 Program Drives Buy Rating Amid Positive Phase 3 Results and Expert Endorsements

    Analyst Oliver McCammon of LifeSci Capital maintains a Buy rating on Candel Therapeutics, citing promising Phase 3 results of CAN-2409 for prostate cancer. The treatment showed a 30% reduction in disease recurrence. Positive endorsements from key opinion leaders and strategic focus support the optimistic view. H.C. Wainwright also reiterated a Buy rating with a $23.00 price target.

    Tip Ranks·
    US
    CADL
    +0.54%
    Tip Ranks·
    US
    CADL
    +0.54%

    Candel Therapeutics Hosts Virtual R&D Day on Immunotherapy

    Candel Therapeutics will host a virtual R&D Day on December 5, 2025, to showcase its viral immunotherapy approach and oncology pipeline, including therapies CAN-2409 and CAN-3110. Despite positive clinical trial results, the company faces financial challenges with no revenue and ongoing cash burn. Analysts have mixed ratings on CADL stock, with a Buy rating and a $25 price target, but also an Underperform rating due to unfavorable technical and valuation metrics.

    Tip Ranks·
    US
    CADL
    +0.54%
    Tip Ranks·
    US
    CADL
    +0.54%
    © 2025 Longbridge｜Disclaimer